Sex: M
Vaccine: RAB, UNK
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: Patient received Rabavert post exposure doses on days one, five, seven and nine after the animal exposure; Case reference number US-BN-2024-001849 is a spontaneous case report initially received from a pharmacist (reference number: USBAV24-0887) on 30-Apr-2024 and concerns a 73-year-old male patient.  The patient's medical history and concomitant medication details were not provided.  On 15-Apr-2024, the patient had contact with the cat. As reported, it was unknown if the patient is immunocompromised or not before the contact.  On 16-Apr-2024, one day after the animal exposure, the patient was vaccinated with the first dose of Rabavert (batch number: FDP00448) at an unknown dose, via intramuscular use, at unknown site of administration for post exposure rabies and with immunoglobulin (brand name: unknown) at an unknown dose, route and site of administration (explicitly coded as 'inappropriate schedule of vaccine administered').  On 20-Apr-2024, five days after the animal exposure the patient was vaccinated with the second dose of Rabavert (batch number: FDP00448) at an unknown dose, via intramuscular use, at unknown site of administration (explicitly coded as 'inappropriate schedule of vaccine administered').  On 22-Apr-2024, seven days after the animal exposure the patient was vaccinated with the third dose of Rabavert (batch number: FDP00448) at an unknown dose, via intramuscular use, at unknown site of administration.  On 24-Apr-2024, nine days after the animal exposure the patient was vaccinated with the fourth dose of Rabavert (batch number: FDP00419) at an unknown dose, via intramuscular use, at unknown site of administration (explicitly coded as 'inappropriate schedule of vaccine administered').  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Rabavert.  No further information was provided.; Reporter's Comments: A 73-year-old male patient was vaccinated with the first dose of Rabavert, one day after the animal exposure, at an unknown dose, route and site of administration which is considered as inappropriate schedule of vaccine administered. Nine days after the animal exposure the patient was vaccinated with the fourth dose of Rabavert, at an unknown dose, via intramuscular use, at unknown site of administration which is also considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Rabavert. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 73-year-old male patient was vaccinated with the first dose of Rabavert, one day after the animal exposure, at an unknown dose, route and site of administration which is considered as inappropriate schedule of vaccine administered. Nine days after the animal exposure the patient was vaccinated with the fourth dose of Rabavert, at an unknown dose, via intramuscular use, at unknown site of administration which is also considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Rabavert. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.